Veristat launched InStat, an automated biostatistics platform designed to cut clinical trial data readout timelines from weeks to days. The company said the system can produce submission-ready tables, listings and figures within five days or less by translating biostatistics requirements into precise specifications executed by validated statistical engines. Clene Nanomedicine is the first sponsor to use InStat for NfL biomarker analyses as part of its accelerated approval pathway under Subpart H for CNM-Au8. Veristat positioned the product as a way to reduce manual analysis delays that can slow regulatory filings and push sponsors into additional data-quality costs. If widely adopted, automated readout workflows could become a competitive differentiator for CROs in a market increasingly focused on speed and predictable deliverables.